The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2- early breast cancer (EBC).
 
Stephen Chia
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Peter Fasching
Honoraria - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; SeaGen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Guardant Health; Hexal; Lilly; Menarini Group; Merck Sharp & Dohme; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Pfizer (Inst); Roche
 
John Crown
Consulting or Advisory Role - Leica Biosystems; Novartis
 
Dennis Slamon
Leadership - 1200 Pharma; Biomarin; Torl Biotherapeutics
Stock and Other Ownership Interests - Amgen; Amgen; BioMarin; Merck Sharp & Dohme; Pfizer; Seagen; Vertex
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer
 
Sherene Loi
Honoraria - Adanate; Astra Zeneca / Daiichi Sankyo; Bicycle Therapeutics; BioNTech SE; Gilead Sciences; Menari Asia Pacific; Mersana; MSD Oncology; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; SK Biopharmaceutical
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
(OPTIONAL) Uncompensated Relationships - Roche
 
Michael Press
Honoraria - Medscape; Physicans' Education Resource
Consulting or Advisory Role - AstraZeneca, Inc; Lilly; Novartis; Torl Biotherapeutics; Zymeworks
 
Miguel Martin
Stock and Other Ownership Interests - AstraZeneca; Pfizer
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech; ROVI Spain; STEMLINE-MENARINI
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii-Sankyo
Other Relationship - AstraZeneca; Novartis; Roche
 
Oleg Lipatov
No Relationships to Disclose
 
Zbighiew Nowecki
No Relationships to Disclose
 
Bozena Kukielka-Budny
No Relationships to Disclose
 
Daniil Stroyakovskiy
No Relationships to Disclose
 
Isabel Blancas
No Relationships to Disclose
 
Kevin Vervier
Employment - Novartis
 
Zheng Li
Employment - Novartis
 
Juan Pablo Zarate Gonzalez
Employment - Novartis
 
Tetiana Taran
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Fei Su
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Aleix Prat
Employment - Reveal Genomics
Leadership - Reveal Genomics
Stock and Other Ownership Interests - Ona Therapeutics; Reveal Genomics
Honoraria - AstraZeneca; Daiichi Sankyo; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Novartis; Ona Therapeutics; Peptomyc; Roche
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Novartis (Inst); Ona Therapeutics (Inst); Reveal Genomics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; TNBC-DX
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Aditya Bardia
Consulting or Advisory Role - Alyssum; Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)